Inicio › Esteatosis hepática › Virginia
Ensayos clínicos de Esteatosis hepática en Virginia
14 estudios sobre Esteatosis hepática buscan participantes en Virginia.
Ciudades en Virginia
Texto oficial del estudio (inglés)
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Virginia Commonwealth University, Richmond
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 28 sept 2026 · NCT05832229A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- University of Virginia Medical Center, Charlottesville
- Richmond Veterans Administration Medical Center, Richmond
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 25 sept 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Eximia Research - Norfolk, Norfolk
- Richmond Veterans Affairs Medical Center (Richmond VA Medical Center), Richmond
- Virginia Commonwealth University (VCU) Medical Center, Richmond
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Norfolk
- Akero Clinical Study Site, Richmond
- Akero Clinical Study Site, Richmond
- y 3 más
ReclutandoFase 3
Edades de 18 a 80 · Todos los sexos · Actualizado el 21 sept 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Manassas
ReclutandoFase 3
Edades de 18 a 75 · Todos los sexos · Actualizado el 17 sept 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GI Alliance Richmond, Richmond
- GI Select Health Research, Richmond
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 9 sept 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- y 1 más
ReclutandoFase 3
Edades de 18 a 80 · Todos los sexos · Actualizado el 3 sept 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
ReclutandoFase 3
Edades de 18 a 75 · Todos los sexos · Actualizado el 3 sept 2026 · NCT06419374A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Richmond
- GSK Investigational Site, Richmond
ReclutandoFase 2
Edades de 18 a 70 · Todos los sexos · Actualizado el 3 ago 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Manassas
- GSK Investigational Site, Norfolk
ReclutandoFase 3
Edades de 18 a 75 · Todos los sexos · Actualizado el 27 jul 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Richmond
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 8 jul 2026 · NCT06920043Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
- Virginia Commonwealth University, Richmond
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 4 jun 2026 · NCT05424003Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- University of Virginia, Charlottesville
- Virginia Common wealth University, Richmond
Reclutando
Edades de 18 a 75 · Todos los sexos · Actualizado el 19 may 2026 · NCT04054310Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
- Virginia Commonwealth University, Richmond
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 abr 2026 · NCT05720663De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.